SIGNIFOR LAR

This brand name is authorized in Australia, Canada, Ecuador, Hong Kong SAR China, Israel, Japan, New Zealand, Singapore, South Africa.

Active ingredients

The drug SIGNIFOR LAR contains one active pharmaceutical ingredient (API):

1	Pasireotide UNII 04F55A7UZ3 - PASIREOTIDE PAMOATE
	Pasireotide is a novel cyclohexapeptide, injectable somatostatin analogue. Pasireotide exerts its pharmacological activity via binding to somatostatin receptors. Somatostatin receptors are expressed in many tissues, especially in neuroendocrine tumours in which hormones are excessively secreted, including ACTH in Cushing’s disease.
	Read more about Pasireotide

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
SIGNIFOR LAR Suspension for injection	MPI, CA: SPM	Health Products and Food Branch (CA)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
H01CB05	Pasireotide	H Systemic hormonal preparations, excl. Sex hormones and insulins → H01 Pituitary and hypothalamic hormones and analogues → H01C Hypothalamic hormones → H01CB Somatostatin and analogues
Discover more medicines within H01CB05

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	10880P, 10882R, 10883T, 10884W, 10886Y, 10887B
CA	Health Products and Food Branch	02437252, 02437260, 02437279, 02480425, 02480433
EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	1898-MEE-0316, 2063-MEE-0516, 2166-MEE-0516
HK	Department of Health Drug Office	64743, 64744, 64745
IL	מִשְׂרַד הַבְּרִיאוּת	7793, 7794, 7795, 9343, 9344
JP	医薬品医療機器総合機構	2499417G1023, 2499417G2020, 2499417G3026, 2499417G4022, 2499417G5029
NZ	Medicines and Medical Devices Safety Authority	18804, 18856, 18857
SG	Health Sciences Authority	15168P, 15169P, 15170P
ZA	Health Products Regulatory Authority	49/32/0272, 49/32/0273, 49/32/0274